Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001213900-25-051149
Filing Date
2025-06-04
Accepted
2025-06-04 16:05:26
Documents
2
Period of Report
2025-06-02

Document Format Files

Seq Description Document Type Size
1 ownership.html 3  
1 ownership.xml 3 1617
2 POWER OF ATTORNEY ea024439201ex24-1_protara.htm EX-24.1 5449
  Complete submission text file 0001213900-25-051149.txt   8691
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Issuer) CIK: 0001359931 (see all company filings)

EIN.: 204580525 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O RAFAEL HOLDINGS, INC. 520 BROAD ST NEWARK NJ 07102
Business Address
CONKLING WILLIAM (Reporting) CIK: 0001852018 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36694 | Film No.: 251023130